

NEW OPTIONS IN HCV THERAPY:

UPDATE
FROM
AASLD
2014

**NEW
OPTIONS** IN HCV
THERAPY:

UPDATE
FROM
AASLD
2014

Tuesday, January 27, 2015
Perry's Steakhouse, Dallas, TX

Eric Lawitz, MD

Vice President of Scientific and Research Development
The Texas Liver Institute
Clinical Professor of Medicine
University of Texas Health Science Center

Agenda

- 6:15 – 6:30 PM Registration and Pre-Assessment
- 6:30 – 6:50 PM Case 1: Liver Failure
- 6:50 – 7:00 PM Discussion
- 7:00 – 7:20 PM Case 2: Cirrhosis
- 7:20 – 7:30 PM Discussion
- 7:30 – 7:50 PM Case 3: Genotype 1 Naive
- 7:50 – 8:00 PM Discussion
- 8:00 – 8:20 PM Case 4: Genotype 3
- 8:20 – 8:30 PM Discussion
- 8:30 – 8:45 PM Post-Assessment

Learning Objectives

As a result of this educational activity, participants will be able to:

1. Delineate which subgroups of patients with HCV infection are likely to benefit from HCV therapy that includes a direct antiviral
2. Implement cost-effective procedures to stage liver disease in patients with HCV infection, before and during antiviral treatment
3. Select the best therapy for HCV patients with specific disease characteristics using evidence-based data
4. List common adverse events associated with HCV therapy that includes a direct antiviral
5. Discuss which HCV therapies may be appropriate for pre- and post- liver transplant patients

Disclosures

Name	Role	Financial Relationship Disclosures
<p>Eric Lawitz, MD Vice President of Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center</p>	<p>Presenter</p>	<p>Bristol-Myers Squibb (Consultant); AbbVie, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen Farmaceutica, Merck & Co., Inc., Novartis, Roche, Theravance Inc. (Principal Investigator (Pi))</p>
<p>Nezam H. Afdhal, MD Professor of Medicine, Harvard Medical School, Chief of Hepatology, Beth Israel Deaconess Medical Center</p>	<p>Content Developer</p>	<p>AbbVie, Achillion, Boehringer-Ingelheim, Echosens, Gilead Sciences, Glaxosmithkline, Janssen, Kadmon, Ligand, Medgenex, Inc, Merck, Novartis, Springbank, Vertex Pharmaceuticals Inc. (Consultant); AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, Vertex Pharmaceuticals Inc. (Principal Investigator (Pi)); Springbank (Stockholder /Other Ownership Interest Holder)</p>
<p>Ira Jacobson, MD Chief of the Division of Gastroenterology and Hepatology Vincent Astor Distinguished Professor of Medicine Medical Director Center for the Study of Hepatitis C Weill Medical College of Cornell University</p>	<p>Content Developer</p>	<p>AbbVie, Achillion, Alnylam, Bristol-Myers Squibb, Enanta, Genentech, Gilead, Janssen, Merck (Consultant); AbbVie, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Merck (Independent Contractor/Researcher); AbbVie, Bristol Myers Squibb, Genentech, Gilead, Janssen (Teacher/Speaker)</p>

Disclosures

Name	Role	Financial Relationship Disclosures
Jane Henderson	Planner	No relevant financial relationships to disclose
Danielle Hepting	CME Staff	No relevant financial relationships to disclose
Leslie Jacus	Planner	No relevant financial relationships to disclose
Donna McMullen	Planner	No relevant financial relationships to disclose
Adnan Said, MD	Content Reviewer	No relevant financial relationships to disclose

Meeting Materials

- Pre-Test
- Brochure
- Disclosures
- CME Credit and Slides
- Notes pages
- Post-Test

NEW OPTIONS IN HCV THERAPY:

UPDATE
FROM
AASLD
2014